Recombinant activated factor VII (rFVIIa) was originally developed for the treatment of
bleeding in patients with haemophilia A or B and inhibitors. Over the past ten years, it has …

Early postpartum hemorrhage remains a significant cause of maternal morbidity and
mortality. Postpartum hemorrhage is most commonly due to uterine atony and often …

The objective of this review was to evaluate and summarize the current literature on the
unlicensed use of the novel agent recombinant activated factor VII (rFVIIa) in the …

BACKGROUND: Spontaneous subcapsular liver hemorrhage is a rare but life-threatening
complication of pregnancy. Optimal management of an expanding hematoma or ruptured …

Recombinant activated factor VII (rFVIIa) is a novel hemostatic agent, originally developed
for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully …

There are increasing reports suggesting that high-dose recombinant human activated factor
VII (rFVIIa) is effective in the treatment and prevention of bleeding in patients with …

HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome associated
with pregnancy results in a significant increase in maternal morbidity and mortality …

Bernard–Soulier syndrome (BSS) is a rare congenital platelet disorder characterized by
defective platelet adhesion and manifested by spontaneous and often profuse bleeding …

Massive obstetric haemorrhage is a life-threatening emergency that remains a major cause
of maternal mortality. Conventional management is aimed at optimising uterine tone …

Recombinant factor VIIa (rFVIIa) has become available for treating people with hemophilia
with inhibitors who experience bleeding or require surgery. It has become apparent that …